Career development activities were a major focus of the initial funding period of the Kidney Cancer SPORE. Many investigators within the DF/HCC Kidney Cancer SPORE have had a longstanding interest and substantial track record in mentoring of junior faculty with an interest in cancer research. The funding of the Kidney Cancer SPORE in 2003 enabled us to establish a formal process for the identification, selection, funding and mentoring of young investigators seeking to pursue careers in basic and clinical aspects of kidney cancer research. In addition, as this field has traditionally received only modest interest from young investigators, it enabled us to focus on marketing to young investigators the potential benefits of pursuing a research career focused on kidney cancer. We feel that our efforts to date have been an unqualified success, with no fewer than 15 young investigators establishing independent academic careers focused at least partially on kidney cancer as a consequence of their interactions with the SPORE. Several of these individuals are leading Kidney Cancer Programs at major academic institutions creating opportunities to multiply the impact of the SPORE on the field (see below and in the Career Development Program Progress Report). We have also been successful at obtaining institutional and outside support for the Career Development Program, which has added to our ability to support young faculty pursuing careers in kidney cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-07
Application #
8079685
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
7
Fiscal Year
2010
Total Cost
$67,797
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Scelo, Ghislaine; Muller, David C; Riboli, Elio et al. (2018) KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res 24:5594-5601
Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95
Gao, Xin; Jegede, Opeyemi; Gray, Connor et al. (2018) Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 16:341-348
Liu, Wenjing; Chen, Binbin; Wang, Yang et al. (2018) RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc Natl Acad Sci U S A 115:E1475-E1484
Iorgulescu, J Bryan; Braun, David; Oliveira, Giacomo et al. (2018) Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med 10:87
Gopal, Raj K; Kübler, Kirsten; Calvo, Sarah E et al. (2018) Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell 34:242-255.e5
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Signoretti, Sabina; Flaifel, Abdallah; Chen, Ying-Bei et al. (2018) Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol :JCO2018792259
Hamieh, Lana; Choueiri, Toni K; Ogórek, Barbara et al. (2018) Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet 14:e1007679
Gao, Xin; McDermott, David F (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Biol Ther 18:947-957

Showing the most recent 10 out of 153 publications